Prevalence and risk factors of sleep disturbances in breast cancersurvivors: systematic review and meta-analyses
- 218 Downloads
Breast cancer remains the most frequently diagnosed malignancy among women worldwide, with rising incidence numbers. In Belgium, one out of eight women will be diagnosed with breast cancer. Fortunately, 80% of those breast cancer patients will still be alive 10 years after diagnosis due to improvements in screening and treatment strategies. However, an important portion of the breast cancer survivors (BCS) will face side effects, such as sleep disturbances, long after treatment ends. It has been demonstrated that untreated insomnia in BCS negatively impacts mood, physical symptoms, pain sensitivity, fatigue, and quality of life. Furthermore, insomnia is increasingly considered an independent risk factor for future depression in BCS. The importance of understanding sleep disturbances in cancer populations has been highlighted and recognized as warranting further research. Therefore, the purpose of this systematic review was to determine the prevalence and the risk factors for the development of sleep disturbances in BCS.
PubMed, Web of Science, and PEDro were systematically screened for studies encompassing data regarding the prevalence or risk factors of sleep disturbances in BCS. If possible, meta-analyses were performed. Subgroup analyses were undertaken based on the methodological quality, study design, type of sleep disturbance, and the use of a measurement tool with strong psychometric properties to investigate significant heterogeneity (I2 > 50%) across studies.
A total of 27 studies were found eligible. The pooled estimate for sleep disturbances prevalence is 0.40 (95% confidence interval (CI) = [0.29–0.52], I2 = 100%, p < 0.00001) and ranged from 0.14 (95% CI = [0.04–0.24]) to 0.93 (95% CI = [0.91–0.95]). Subgroup analyses did not reduce the heterogeneity among studies. Meta-analyses were performed for seven risk factors. Significant differences for the odds of developing sleep disturbances were found for hot flashes (pooled OR (ORp) 2.25, 95% CI = [1.64–3.08], I2 = 0%, p = 0.90), race (ORp 2.31, 95% CI = [1.56–3.42], I2 = 0%, p = 0.47), and menopause (ORp 1.84, 95% CI = [1.11–3.06], I2 = 0%, p = 0.70). After withdrawing the studies that did not rely on the use of a measurement tool with strong psychometric properties, pain (ORp 2.31, 95% CI = [1.36–3.92], I2 = 27%, p = 0.25), depressive symptoms (ORp 3.20, 95% CI [2.32–4.42], I2 = 0%, p = 0.63), and fatigue (ORp 2.82, 95% CI = [1.98–4.02], I2 = 0%, p = 0.60) became significant as well, with a substantial decrease of heterogeneity.
Prevalence for sleep disturbances ranged from 0.14 to 0.93 with the vast majority of the studies investigating insomnia and sleep-wake disturbances. High heterogeneity makes it difficult to draw firm conclusions. Pain, depressive symptoms, hot flashes, fatigue, non-Caucasian race, and menopausal status were significantly associated with increased odds for developing sleep disturbances.
KeywordsInsomnia Sleep disturbances Breast cancer survivors Risk factors Determinants Prevalence
Compliance with ethical standards
Conflict of interest
The authors have full control of all data acquired from included manuscripts and agree to allow the journal to review the data if requested.
- 1.Fitzmaurice C et al (2016) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA OncolGoogle Scholar
- 2.Coleman MP, Quaresma M, Berrino F, Lutz JM, de Angelis R, Capocaccia R, Baili P, Rachet B, Gatta G, Hakulinen T, Micheli A, Sant M, Weir HK, Elwood JM, Tsukuma H, Koifman S, E Silva GA, Francisci S, Santaquilani M, Verdecchia A, Storm HH, Young JL, CONCORD Working Group (2008) Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol 9(8):730–756CrossRefPubMedGoogle Scholar
- 4.American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders-IV-TR. American Psychiatric Association, Washington, DCGoogle Scholar
- 5.Colten H, Altevogt B (2006) Sleep disorders and sleep deprivation: an unmet public health problem, vol 2007. National Academies Press, Washington, DCGoogle Scholar
- 10.Morin CM (1993) Insomnia: psychological assessment and management. Guilford PressGoogle Scholar
- 17.Palesh OG, Roscoe JA, Mustian KM, Roth T, Savard J, Ancoli-Israel S, Heckler C, Purnell JQ, Janelsins MC, Morrow GR (2010) Prevalence, demographics, and psychological associations of sleep disruption in patients with Cancer: University of Rochester Cancer Center–Community Clinical Oncology Program. J Clin Oncol 28(2):292–298CrossRefPubMedGoogle Scholar
- 19.Office of Cancer Survivorship, NCI About cancer survivorship research: survivorship definitions. 2012. Available from: http://cancercontrol.cancer.gov/ocs/researcher_factsheet.pdf
- 20.Elmagarmid A et al (2014) Rayyan: a systematic reviews web app for exploring and filtering searches for eligible studies for Cochrane Reviews. In: Evidence-informed public health: opportunities and challenges. Abstracts of the 22nd Cochrane Colloquium. Wiley, HyderabadGoogle Scholar
- 21.Green, S., et al., Chapter 1: what is a systematic review. Cochrane handbook for systematic reviews of interventions version, 2008. 5(0)Google Scholar
- 27.McPheeters ML et al (2012) Closing the quality gap: revisiting the state of the science (vol. 3: quality improvement interventions to address health disparities). Evid Rep Technol Assess (Full Rep) (208.3):1–475Google Scholar
- 33.Alfano CM, Lichstein KL, Vander Wal GS, Smith AW, Reeve BB, McTiernan A, Bernstein L, Baumgartner KB, Ballard-Barbash R (2011) Sleep duration change across breast cancer survivorship: associations with symptoms and health-related quality of life. Breast Cancer Res Treat 130(1):243–254CrossRefPubMedPubMedCentralGoogle Scholar
- 34.Arraras JI et al (2016) Quality of life in long-term premenopausal early-stage breast cancer survivors from Spain. Effects of surgery and time since surgery. J Buon 21(5):1090–1098Google Scholar
- 42.Lowery-Allison AE et al (2017) Sleep problems in breast cancer survivors 1-10 years posttreatment. Palliat Support Care:1–10Google Scholar
- 65.Partridge A, Gelber S, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Winer E (2007) Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from international breast Cancer study group trials V and VI. Eur J Cancer 43(11):1646–1653CrossRefPubMedGoogle Scholar
- 68.Morales L, Neven P, Timmerman D, Christiaens MR, Vergote I, van Limbergen E, Carbonez A, van Huffel S, Ameye L, Paridaens R (2004) Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. Anti-Cancer Drugs 15(8):753–760CrossRefPubMedGoogle Scholar
- 70.Rumble ME, Keefe FJ, Edinger JD, Affleck G, Marcom PK, Shaw HS (2010) Contribution of cancer symptoms, dysfunctional sleep related thoughts, and sleep inhibitory behaviors to the insomnia process in breast Cancer survivors: a daily process analysis. Sleep 33(11):1501–1509CrossRefPubMedPubMedCentralGoogle Scholar